Beta-lactamase inhibitor combinations with extended-spectrum penicillins: factors influencing antibacterial activity against enterobacteriaceae and Pseudomonas aeruginosa.
Production of beta-lactamases is the most common mechanism by which gram-negative bacteria express resistance to beta-lactam antibiotics. One successful method of circumventing the threat of plasmid-encoded beta-lactamases is to combine inhibitors of these enzymes with a penicillin. Currently, four inhibitor-penicillin combinations are in clinical use: ampicillin-sulbactam, amoxicillin-clavulanate, ticarcillin-clavulanate, and piperacillin-tazobactam. Of these, ticarcillin-clavulanate and piperacillin-tazobactam have the broadest spectra of activity that includes Pseudomonas aeruginosa. Many factors influence the activity and pharmacodynamics of these combinations, including potency of both agents, pharmacokinetics of the inhibitor, type and quantity of beta-lactamase produced by the target bacterium, and potential for the inhibitor to induce expression of chromosomal cephalosporinases in the target bacterium. Although ticarcillin-clavulanate and piperacillin-tazobactam have similar spectra of activity, they have many differences. Most notable are increased potency of piperacillin against Enterobacteriaceae and P aeruginosa, increased activity of piperacillin-tazobactam against gram-negative pathogens producing penicillin-sensitive enzyme (PSE)-class beta-lactamase or hyperproducing other plasmid-encoded beta-lactamases, and the more favorable pharmacokinetics of tazobactam. In the treatment of P. aeruginosa infections, the potential for clavulanate to induce expression of chromosomal cephalosporinase and antagonize antibacterial activity of ticarcillin is a concern, especially in patients who lack protective host defenses. These are not concerns with piperacillin-tazobactam.
Lister
P D
PD
Center for Research in Anti-Infectives and Biotechnology, Department of Medical Microbiology and Immunology, Creighton University School of Medicine, Omaha, Nebraska 68178, USA.
D019818:Clavulanic Acid / Q000008:administration & dosage / Q000493:pharmacokinetics / Q000494:pharmacology*; D004359:Drug Therapy, Combination; D004755:Enterobacteriaceae / Q000187:drug effects*; D004791:Enzyme Inhibitors / Q000008:administration & dosage / Q000494:pharmacology*; D010397:Penicillanic Acid / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000493:pharmacokinetics / Q000494:pharmacology*; D010403:Penicillin Resistance; D010878:Piperacillin / Q000008:administration & dosage / Q000493:pharmacokinetics / Q000494:pharmacology*; D011550:Pseudomonas aeruginosa / Q000187:drug effects*; D000078142:Tazobactam; D013982:Ticarcillin / Q000008:administration & dosage / Q000493:pharmacokinetics / Q000494:pharmacology*; D001618:beta-Lactamases / Q000096:biosynthesis* / Q000378:metabolism
D004791:Enzyme Inhibitors; D019818:Clavulanic Acid; D010397:Penicillanic Acid; D001618:beta-Lactamases; D013982:Ticarcillin; D000078142:Tazobactam; D010878:Piperacillin